Skip to main content

Table 1 Demographic and clinical characteristics of patients at inclusion

From: Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis

  Population (N = 291)
Age (mean ± SD; years) 36.9 ± 9.3
Gender  
   Women 218 (74.9%)
   Men 67 (23.0%)
   Missing data 6 (2.1%)
Time since diagnosis (mean ± SD; years) 4.31 ± 5.47
ARR since diagnosis (mean ± SD) 3.82 ± 3.54
   No relapses 14 (4.8%)
   Up to 2 relapses 111 (38.1%)
   3–5 relapses 100 (34.4%)
   More than 5 relapses 57 (19.6%)
ARR within previous 12 months (mean ± SD) 1.71 ± 0.88
EDSS at treatment initiation (mean ± SD) 2.58 ± 1.44
   EDSS 0–2 127 (43.6%)
   EDSS 3–5 121 (41.6%)
   EDSS 6–7 16 (5.5%)
   Missing data 27 (9.3%)
  1. ARR: annualised relapse rate: EDSS: Expanded Disability Status Scale; SD: standard deviation.